Patent ID: 11899027
Assignee: RUBIO METABOLOMICS, S.L.U.
Field: Measurement (Instruments)
Classification: CPC G | IPC G

Claim 4:
5. The method according to claim 1, wherein the subject suffering from NAFLD has been previously diagnosed of NAFLD by an in vitro method that comprises:
(i) determining in a sample from the subject the levels of one or more metabolic markers selected from the group consisting of:
(a) metabolic marker TG(44:1) comprising at least one of analytes TG(14:0+18:1+12:0) and TG(16:0+16:1+12:0);
(b) metabolic marker TG(46:0) comprising analyte TG(16:0+16:0+14:0);
(c) metabolic marker TG(48:0) comprising analyte TG(16:0/16:0/16:0);
(d) metabolic marker TG(48:1) comprising at least one of analytes TG(14:0+18:1+16:0) and TG(16:0+16:1+16:0);
(e) metabolic marker TG(49:1) comprising analyte TG(15:0+18:1+16:0);
(f) metabolic marker TG(50:2) comprising at least one of analytes TG(16:0+18:1+16:1), TG(18:1+18:1+14:0), and TG(16:0+18:2+16:0);
(g) metabolic marker TG(52:1) comprising analyte TG (16:0+18:1+18:0);
(h) metabolic marker TG(53:0) comprising at least one of analytes TG(17:0+18:0+18:0) and TG(20:0+17:0+16:0);
(i) metabolic marker TG(53:1) comprising analyte TG(18:0+18:1+17:0);
(j) metabolic marker TG(54:5) comprising analyte TG(18:1+20:4+16:0); and
(k) metabolic marker TG(58:2) comprising analyte TG(18:1+22:0+18:1), and

(ii) comparing the levels obtained in (i) to a reference value to obtain a relative value, wherein the subject is diagnosed with NAFLD according to a score that is obtained by introducing the relative values of said metabolic marker(s) in a logistic regression model.